 | • レポートコード：MRC2207A098 • 出版社/出版日：Transparency Market Research / 2022年5月 • レポート形態：英文、PDF、189ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| トランスペアレンシー・マーケット・リサーチ社の本調査レポートでは、世界の髄膜炎菌ワクチン市場について総合的に調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、種類別（多糖類、結合型ワクチン、混合ワクチン、MenBワクチン、その他）分析、エンドユーザー別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの内容をまとめております。なお、本書に掲載されている企業情報にはSanofi SA、Novartis International、GlaxoSmithKline plc、Pfizer Inc.、Nuron Biotech.、JN-International Medical Corporation.、Serum Institute of India Ltd、Baxter Internationalなどが含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界の髄膜炎菌ワクチン市場規模：種類別（多糖類、結合型ワクチン、混合ワクチン、MenBワクチン、その他） ・世界の髄膜炎菌ワクチン市場規模：エンドユーザー別 ・世界の髄膜炎菌ワクチン市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Meningococcal Vaccines Market – Scope of Report
TMR’s report on the global meningococcal vaccines market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global meningococcal vaccines market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global meningococcal vaccines market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the meningococcal vaccines market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global meningococcal vaccines market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global meningococcal vaccines market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global meningococcal vaccines market.
The report delves into the competitive landscape of the global meningococcal vaccines market. Key players operating in the global meningococcal vaccines market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global meningococcal vaccines market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market meningococcal vaccines.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Meningococcal Vaccines Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Meningococcal Vaccines Market Analysis and Forecast, 2021–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Regulatory Scenario by Region/globally
5.3. Covid-19 Impact analysis
6. Global Meningococcal Vaccines Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031
6.3.1. Polysaccharide
6.3.1.1. Menomune
6.3.1.2. Mencevax
6.3.1.3. NmVac4
6.3.1.4. Others
6.3.2. Conjugate Vaccines
6.3.2.1. Menactra
6.3.2.2. Menveo
6.3.2.3. NeisVac-C
6.3.2.4. Nimenrix
6.3.2.5. Others
6.3.3. Combination Vaccines
6.3.3.1. MenHibrix
6.3.3.2. Menitorix
6.3.4. Men B Vaccines
6.3.4.1. Bexsero
6.3.4.2. Trumenba
6.4. Global Meningococcal Vaccines Market Attractiveness, by Type
7. Global Meningococcal Vaccines Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031
7.3.1. Retail Pharmacies
7.3.2. Hospital Pharmacies
7.3.3. Others (online pharmacies, drug stores)
7.4. Global Meningococcal Vaccines Market Attractiveness, by End-user
8. Global Meningococcal Vaccines Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Meningococcal Vaccines Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Meningococcal Vaccines Market Attractiveness, by Country/Region
9. North America Meningococcal Vaccines Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031
9.2.1. Polysaccharide
9.2.1.1. Menomune
9.2.1.2. Mencevax
9.2.1.3. NmVac4
9.2.1.4. Others
9.2.2. Conjugate Vaccines
9.2.2.1. Menactra
9.2.2.2. Menveo
9.2.2.3. NeisVac-C
9.2.2.4. Nimenrix
9.2.2.5. Others
9.2.3. Combination Vaccines
9.2.3.1. MenHibrix
9.2.3.2. Menitorix
9.2.4. Men B Vaccines
9.2.4.1. Bexsero
9.2.4.2. Trumenba
9.3. North America Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031
9.3.1. Retail Pharmacies
9.3.2. Hospital Pharmacies
9.3.3. Others (online pharmacies, drug stores)
9.4. North America Meningococcal Vaccines Market Value Forecast, by Country, 2021–2031
9.4.1. U.S.
9.4.2. Canada
9.5. North America Meningococcal Vaccines Market Attractiveness Analysis
9.5.1. By Type
9.5.2. By End-user
9.5.3. By Country
10. Europe Meningococcal Vaccines Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031
10.2.1. Polysaccharide
10.2.1.1. Menomune
10.2.1.2. Mencevax
10.2.1.3. NmVac4
10.2.1.4. Others
10.2.2. Conjugate Vaccines
10.2.2.1. Menactra
10.2.2.2. Menveo
10.2.2.3. NeisVac-C
10.2.2.4. Nimenrix
10.2.2.5. Others
10.2.3. Combination Vaccines
10.2.3.1. MenHibrix
10.2.3.2. Menitorix
10.2.4. Men B Vaccines
10.2.4.1. Bexsero
10.2.4.2. Trumenba
10.3. Europe Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031
10.3.1. Retail Pharmacies
10.3.2. Hospital Pharmacies
10.3.3. Others (online pharmacies, drug stores)
10.4. Europe Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Europe Meningococcal Vaccines Market Attractiveness Analysis
10.5.1. By Type
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Meningococcal Vaccines Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Asia Pacific Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031
11.2.1. Polysaccharide
11.2.1.1. Menomune
11.2.1.2. Mencevax
11.2.1.3. NmVac4
11.2.1.4. Others
11.2.2. Conjugate Vaccines
11.2.2.1. Menactra
11.2.2.2. Menveo
11.2.2.3. NeisVac-C
11.2.2.4. Nimenrix
11.2.2.5. Others
11.2.3. Combination Vaccines
11.2.3.1. MenHibrix
11.2.3.2. Menitorix
11.2.4. Men B Vaccines
11.2.4.1. Bexsero
11.2.4.2. Trumenba
11.3. Asia Pacific Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031
11.3.1. Retail Pharmacies
11.3.2. Hospital Pharmacies
11.3.3. Others (online pharmacies, drug stores)
11.4. Asia Pacific Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Meningococcal Vaccines Market Attractiveness Analysis
11.5.1. By Type
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Latin America Meningococcal Vaccines Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Latin America Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031
12.2.1. Polysaccharide
12.2.1.1. Menomune
12.2.1.2. Mencevax
12.2.1.3. NmVac4
12.2.1.4. Others
12.2.2. Conjugate Vaccines
12.2.2.1. Menactra
12.2.2.2. Menveo
12.2.2.3. NeisVac-C
12.2.2.4. Nimenrix
12.2.2.5. Others
12.2.3. Combination Vaccines
12.2.3.1. MenHibrix
12.2.3.2. Menitorix
12.2.4. Men B Vaccines
12.2.4.1. Bexsero
12.2.4.2. Trumenba
12.3. Latin America Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031
12.3.1. Retail Pharmacies
12.3.2. Hospital Pharmacies
12.3.3. Others (online pharmacies, drug stores)
12.4. Latin America Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Meningococcal Vaccines Market Attractiveness Analysis
12.5.1. By Type
12.5.2. By End-user
12.5.3. By Country/Sub-region
13. Middle East & Africa Meningococcal Vaccines Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031
13.2.1. Polysaccharide
13.2.1.1. Menomune
13.2.1.2. Mencevax
13.2.1.3. NmVac4
13.2.1.4. Others
13.2.2. Conjugate Vaccines
13.2.2.1. Menactra
13.2.2.2. Menveo
13.2.2.3. NeisVac-C
13.2.2.4. Nimenrix
13.2.2.5. Others
13.2.3. Combination Vaccines
13.2.3.1. MenHibrix
13.2.3.2. Menitorix
13.2.4. Men B Vaccines
13.2.4.1. Bexsero
13.2.4.2. Trumenba
13.3. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031
13.3.1. Retail Pharmacies
13.3.2. Hospital Pharmacies
13.3.3. Others (online pharmacies, drug stores)
13.4. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Middle East & Africa Meningococcal Vaccines Market Attractiveness Analysis
13.5.1. By Type
13.5.2. By End-user
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2021
14.3. Company Profiles
14.3.1. Sanofi SA
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Strategic Overview
14.3.2. Novartis International
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Strategic Overview
14.3.3. GlaxoSmithKline plc
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Strategic Overview
14.3.4. Pfizer Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Strategic Overview
14.3.5. Nuron Biotech.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Strategic Overview
14.3.6. JN-International Medical Corporation.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Strategic Overview
14.3.7. Serum Institute of India Ltd
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Strategic Overview
14.3.8. Baxter International
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Strategic Overview
Table 01: Global Meningococcal Vaccine Market Pipeline Analysis
Table 02: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022–2031
Table 03: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide Meningococcal Vaccines, 2022–2031
Table 04: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Meningococcal Vaccines, 2022–2031
Table 05: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Meningococcal Vaccines, 2022–2031
Table 06: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Meningococcal Vaccines, 2022–2031
Table 07: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022–2031
Table 08: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Region, 2022–2031
Table 09: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country, 2022–2031
Table 10: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022–2031
Table 11: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022–2031
Table 12: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022–2031
Table 13: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022–2031
Table 14: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022–2031
Table 15: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022–2031
Table 16: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022–2031
Table 17: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022–2031
Table 18: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022–2031
Table 19: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022–2031
Table 20: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022–2031
Table 21: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022–2031
Table 22: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022–2031
Table 23: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022–2031
Table 24: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022–2031
Table 25: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022–2031
Table 26: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022–2031
Table 27: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022–2031
Table 28: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022–2031
Table 29: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022–2031
Table 30: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022–2031
Table 31: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022–2031
Table 32: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022–2031
Table 33: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022–2031
Table 34: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022–2031
Table 35: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022–2031
Table 36: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022–2031
Table 37: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022–2031
Table 38: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022–2031
Table 39: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022–2031
Table 40: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022–2031
Table 41: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022–2031
Table 42: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022–2031
Table 43: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022–2031